Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program
- Laws, H.-J.
- Fukutake, K.
- Lopez-Fernandez, M.F.
- Li, Y.
- Seifert, W.
- Tagliaferri, A.
ISSN: 1600-0609, 0902-4441
Ano de publicación: 2023
Volume: 111
Número: 2
Páxinas: 293-299
Tipo: Artigo